2 Sources
[1]
Venture firm Flagship bets £100 million to build AI-driven drug companies in Britain
LONDON, Nov 16 (Reuters) - Flagship Pioneering is opening its first lab for creating companies outside the United States, putting £100 million ($131.94 million) behind a new UK-based effort to fund and build AI-driven biotech companies, the venture firm said on Monday. The move is a first for a
[2]
Venture firm Flagship bets £100 million to build AI-driven drug companies in Britain
LONDON, Nov 16 (Reuters) - Flagship Pioneering is opening its first lab for creating companies outside the United States, putting £100 million ($131.94 million) behind a new UK-based effort to fund and build AI-driven biotech companies, the venture firm said on Monday. The move is a first for a
Share
Copy Link
Flagship Pioneering, the US venture firm behind Moderna, will put £100 million ($131.94 million) into building AI-driven biotech companies in Britain
1
. The commitment funds a new company-creation lab anchored at the firm's London office, announced on November 161
.It is the first company-creation lab Flagship has opened outside the United States after more than 25 years in which it operated only in the US
1
. Flagship has built more than 130 companies over that run, including Moderna, the mRNA drug maker that made the firm's name2
.Noubar Afeyan, Flagship's founder and CEO and Moderna's chairman, said the National Health Service and its accumulated patient data are the country's main draw
1
. Real-world patient records let researchers start from evidence about disease to find drug targets, rather than the other way around1
.Flagship's portfolio company Generate Biomedicines has already run the approach in Britain, completing an early-stage trial in Manchester of an asthma drug designed with AI
2
.The lab is also the product of three years of groundwork. Flagship set up its London office in 2023, beside the Francis Crick Institute in King's Cross. The team there has since built partnerships with academia, government bodies and regulators
1
.The plan is company creation from scratch. Flagship will not buy into existing companies; it plans partnerships with universities, corporations and funders instead
1
. It expects to hire roughly 50 scientist-entrepreneurs and operators in Britain to start2
.The £100 million is the opening commitment. Afeyan said Flagship hopes the money will pull in £500 million or more from partners
1
, though that figure is an aspiration rather than secured cash1
. Afeyan said the firm concluded the move might well prove the right next step in its evolution1
.AI, per Afeyan, will be part of everything the lab does, from inventing drugs to running trials
1
. But he cautioned that AI's use in the field is at an early stage2
. "We're in an age where I think AI's most fundamental contribution in the first instance will be to shed a light on actually what's happening mechanistically in diseases," Afeyan said1
.Related Stories
Summarized by
Navi
08 Jun 2026•Business and Economy

29 Oct 2024•Science and Research

31 Mar 2025•Business and Economy
